Cabaletta Bio Q3 net loss widens 18% to $53.05 million

By Public Technologies
  • Cabaletta Bio’s third-quarter 2026 net loss widened 18% year over year to $53.05 million.
  • Research and development expenses rose 18% year over year to $47.14 million.
  • Cash and cash equivalents totaled $299.4 million at September 30, supporting an operating runway into the first quarter of 2028.
  • Registrational myositis topline results are expected in the second half of 2027, with a BLA submission planned for the first quarter of 2028.
  • A registrational systemic sclerosis cohort opened for enrollment, targeting patients with interstitial lung disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870497) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk